Torrent Pharma Gets Zero USFDA Observations for Dahej Plant
Written By : Parthika Patel
Published On 2026-01-25 18:03 GMT | Update On 2026-01-25 18:03 GMT
Advertisement
New Delhi: Torrent Pharmaceuticals Limited has informed that the United States Food and Drug Administration (USFDA) has completed an inspection of the company's manufacturing facility located at Dahej, Gujarat, with zero observations, indicating full compliance with regulatory requirements.
In an intimation to the exchanges, Torrent Pharmaceuticals stated that the USFDA conducted the inspection at its Dahej manufacturing unit over a five-day period, from January 19, 2026 to January 23, 2026. The company confirmed that the inspection has been formally concluded without any regulatory observations being issued.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.